Our remote monitoring technology has helped us build the world’s largest cardiac data network, making care more accurate, comprehensive and efficient.
Processing over 4 billion heartbeats a day
Monitoring over 1 Million patients per year
Each month more than 30,000 physicians refer patients to our products
Provided over 1 million reports to physicians with information for diagnosis and therapy management
Over 50,000 monitoring devices – 29 U.S. patents and 34 international patents issued
Over $300 million invested in the technology and service platform
Find product details, quick start guides and more at myheartmonitor.com.
BioTelemetry, Inc. (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a partnership with Apple (NASDAQ:AAPL) to provide cardiac monitoring services in conjunction with the Apple Heart Study.
November 30, 2017
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that BioTelemetry Research, their leading global imaging and cardiac core lab, and AMRA, the international leader in body composition analysis, have formed an exclusive alliance for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials.
October 25, 2017
BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2017 earnings on Tuesday, August 8 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, August 8, 2017. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.
July 31, 2017